Welcome to our dedicated page for 22Nd Century news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22Nd Century stock.
22nd Century Group (NASDAQ: XXII) pioneers plant-based solutions for tobacco harm reduction through advanced biotechnology. This news hub provides investors and stakeholders with essential updates on regulatory milestones, product innovations, and operational developments central to the company's mission of reducing nicotine addiction.
Access authoritative coverage of FDA communications, VLN product advancements, and manufacturing capacity updates. Our curated collection includes earnings reports, patent filings, and scientific research collaborations that demonstrate 22nd Century's leadership in developing reduced-nicotine tobacco products.
Key updates feature the company's Modified Risk Tobacco Product authorization, progress in international market expansion, and innovations in nicotine biosynthesis control. Regular updates ensure informed tracking of this biotechnology firm's unique position at the intersection of public health and commercial tobacco production.
Bookmark this page for streamlined access to verified corporate announcements and analysis-free reporting on 22nd Century's progress in redefining tobacco consumption through science-driven solutions.
22nd Century Group (XXII) is committed to reducing smoking harm by securing Modified Risk Tobacco Product (MRTP) authorization from the FDA for its VLN® cigarette, which contains 95% less nicotine than major brands. The company plans to launch VLN® within 90 days of receiving authorization, supported by new patents improving genetic control over nicotine levels. Net sales rose 13.1% year-over-year to $7.3 million, with operating loss improving by $3.6 million. 22nd Century's cash position stands at $26.8 million, indicating strong liquidity for future operations.
22nd Century Group (NYSE American: XXII) will host a live audio webcast on November 5, 2020, at 8:00 a.m. EST to discuss its 2020 third quarter results, which will be released at 7:00 a.m. EST that day. CEO James A. Mish and other executives will outline a new strategic plan focusing on innovation, growth opportunities, and company re-alignment. A Q&A session will follow, allowing analysts and investors to interact directly. The webcast will be available on the Company’s Investor Relations page, with an archived replay accessible post-event.
22nd Century Group, Inc. (NYSE American: XXII) announced participation in the FDA’s Tobacco and Nicotine Products Regulation Conference, highlighting advancements in reduced nicotine technology.
Mitchell R. Zeller from the FDA will discuss the Comprehensive Plan on October 21, 2020, while 22nd Century's regulatory VP, John Pritchard, will speak on nicotine and harm reduction on October 22, 2020. Pritchard emphasized that limiting nicotine could help 5 million adult smokers quit within a year and save over 8 million lives by century's end. The company aims to support the FDA's efforts in reducing nicotine standards across the tobacco industry.
22nd Century Group has been awarded a new U.S. patent (No. 10,669,552) allowing precise genetic control over nicotine levels in various tobacco plant varieties. This technology can facilitate the introduction of very low nicotine traits into multiple tobacco types, supporting the FDA’s plan to limit nicotine content in cigarettes. The company is also preparing to launch its VLN® cigarettes, which contain 95% less nicotine than traditional cigarettes, pending FDA approval. This innovation aligns with their mission to reduce smoking harm and disrupt the $100 billion U.S. tobacco market.
22nd Century Group (NYSE American: XXII) reported an update from CEO James A. Mish, emphasizing the urgency of their Modified Risk Tobacco Product (MRTP) application with the FDA for their VLN® reduced nicotine cigarettes. The company is optimistic about receiving authorization, which could significantly boost market value by capturing just 0.25% of the U.S. tobacco market, potentially leading to a 5-10x increase in market capitalization. Additionally, the firm aims to advance its hemp/cannabis technology while holding over 200 patents.
22nd Century Group (NYSE American: XXII) has appointed Dr. Michael Koganov to its Board of Directors, enhancing the company's leadership in plant biotechnology. Dr. Koganov will chair the Scientific and Technical Advisory Committee and join the Finance Committee. He brings significant expertise in developing natural plant-based technologies, with a history of success in the life sciences sector. His appointment is expected to strengthen 22nd Century's strategic initiatives and R&D efforts, especially as the company focuses on innovative solutions in the tobacco and cannabis markets.
22nd Century Group (NYSE American: XXII) will present at the LD Micro 500 Virtual Conference on September 3, 2020, at 4:20 p.m. ET. The executive team will be available for one-on-one meetings with investors on September 3 and 4. A live webcast will be accessible on the company’s Investors webpage, with archived replays available post-event. The company specializes in plant-based biotechnology and has innovative products, such as reduced nicotine tobacco. Their expertise extends to developing unique varieties in hemp and cannabis, holding over 200 patents.
22nd Century Group (NYSE American: XXII) announced a live audio webcast scheduled for August 6, 2020, at 8:00 a.m. ET to discuss its second quarter 2020 results. A press release revealing the results will be issued at 7:00 a.m. ET on the same day. Key executives, including CEO James A. Mish, COO Michael Zercher, and CFO John Franzino, will present during the event. Investors can access the webcast through the company's Investor Relations website, and an archived replay will be available afterward.
22nd Century Group has appointed James A. Mish as the new CEO effective June 22, 2020, and John Franzino as the CFO immediately. Mish brings significant executive leadership experience in pharmaceuticals and cannabinoids, previously leading Noramco and its spinoff, Purisys. The company anticipates growth through its reduced nicotine cigarettes and new cannabinoid products. Franzino, with a background in finance for tobacco and alcoholic beverages, is expected to navigate the company through its growth phase. Former CFO Andrea Jentsch resigned for personal reasons.
FAQ
What is the current stock price of 22Nd Century (XXII)?
What is the market cap of 22Nd Century (XXII)?
